Aprea Therapeutics

Focus: Aprea Therapeutics is a small molecule oncology-focused biotech company headquartered in Doylestown, PA, developing cancer drugs with a lead program in myelodysplastic syndrome. The company operates as a pre-revenue or early-stage biotech with a focused pipeline in hematologic malignancies and solid tumors.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Aprea Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Aprea Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

APR-246

Hematologic Neoplasms

Phase 1

Clinical Trials (1)

NCT00900614Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

Phase 1

Help build intelligence for Aprea Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead program eprenetapopt is in Phase 3 with 11 active trials, offering clear near-term clinical catalysts and value inflection potential
Oncology focus in myelodysplastic syndrome addresses an underserved patient population with significant commercial opportunity
Small, focused company structure enables rapid career progression and meaningful individual impact on drug development decisions

Watch Out For

No active job openings reported, suggesting limited near-term hiring and potential hiring freeze
Early-stage pipeline outside lead program (three Phase 1 programs) limits revenue diversification and long-term stability
Missing critical data on funding, cash position, and headcount raises questions about runway and financial sustainability

Generated by Claude from Aprea Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

APR-246

Myeloid Malignancy

Phase 1

Clinical Trials (1)

NCT04214860APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Phase 1

APR-1051

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT06260514Study of APR-1051 in Patients With Advanced Solid Tumors

Phase 1

APR-548

Myelodysplastic Syndrome

Phase 1

Clinical Trials (1)

NCT04638309APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

Phase 1

APR-246

Myelodysplastic Syndrome

Phase 1/2

Clinical Trials (1)

NCT03072043Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

Phase 1/2

ATRN-119

Advanced Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT04905914Study Of ATRN-119 In Patients With Advanced Solid Tumors

Phase 1/2

APR-246

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

Phase 1/2

Clinical Trials (1)

NCT02098343p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

Phase 1/2

APR-246

Melanoma

Phase 1/2

Clinical Trials (1)

NCT03391050A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Phase 1/2

APR-246

Myelodysplastic Syndrome With Gene Mutation

Phase 1/2

Clinical Trials (1)

NCT03588078Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Phase 1/2

APR-246

High-grade Serous Ovarian Cancer

Phase 2

Clinical Trials (1)

NCT03268382p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Phase 2

APR-246

Acute Myeloid Leukemia or Myelodysplastic Syndromes

Phase 2

Clinical Trials (1)

NCT03931291APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Phase 2

eprenetapopt

Myelodysplastic Syndrome

Phase 3

Clinical Trials (2)

NCT04419389APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

Phase 1/2

NCT04383938Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Phase 1/2

APR-246 + azacitidine

MDS

Phase 3

Clinical Trials (1)

NCT03745716APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Phase 3

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 14 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

12 pipeline

Marketed

Pipeline